NIASTASE Side Effects

6584853-7 | Cerebellar Infarction, Cerebral Infarction
on Feb 08, 2010 Female patient from CANADA , 83 years of age, was diagnosed with aortic valve replacement and was treated with Niastase (View Usage). Patient experienced the following unwanted or unexpected effects: cerebellar infarction, cerebral infarction. Niastase dosage: 2.4 Mg, Unk. During the same period patient was treated with CEFAZOLIN (View Cefazolin Review and Cefazolin Label ), TYLENOL (CAPLET) (View Tylenol (caplet) Review and Tylenol (caplet) Label ), MIDAZOLAM HCL (View Midazolam Hcl Review and Midazolam Hcl Label ), MORPHINE (View Morphine Review and Morphine Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), FENTANYL /00174602/ (View Fentanyl /00174602/ Review and Fentanyl /00174602/ Label ), RANITIDINE (View Ranitidine Review and Ranitidine Label ).

6529453-X | Cerebellar Infarction, Cerebral Infarction
Patient was taking Niastase (View Usage). Patient had the following side effects: cerebellar infarction, cerebral infarction on Dec 31, 2009 from CANADA Additional patient health information: Female patient , 83 years of age, was diagnosed with aortic valve replacement and. Niastase dosage: 2.4 Mg, Unk. During the same period patient was treated with CEFAZOLIN (View Cefazolin Review and Cefazolin Label ), TYLENOL (CAPLET) (View Tylenol (caplet) Review and Tylenol (caplet) Label ), MIDAZOLAM HCL (View Midazolam Hcl Review and Midazolam Hcl Label ), MORPHINE (View Morphine Review and Morphine Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), FENTANYL /00174602/ (View Fentanyl /00174602/ Review and Fentanyl /00174602/ Label ), RANITIDINE (View Ranitidine Review and Ranitidine Label ).

6457422-7 | Cerebellar Infarction, Cerebral Infarction
Adverse event was reported on Nov 19, 2009 by a Female patient taking Niastase (View Usage) (Dosage: 2.4 Mg, Unk) was diagnosed with aortic valve replacement and. Location: CANADA , 83 years of age, After Niastase was administered, patient had the following side effects: cerebellar infarction, cerebral infarction. During the same period patient was treated with CEFAZOLIN (View Cefazolin Review and Cefazolin Label ), TYLENOL (CAPLET) (View Tylenol (caplet) Review and Tylenol (caplet) Label ), MIDAZOLAM HCL (View Midazolam Hcl Review and Midazolam Hcl Label ), MORPHINE (View Morphine Review and Morphine Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), FENTANYL /00174602/ (View Fentanyl /00174602/ Review and Fentanyl /00174602/ Label ), RANITIDINE (View Ranitidine Review and Ranitidine Label ).

6156577-1 | Cardio-respiratory Arrest, Hypoxic Encephalopathy, Pulmonary Embolism
on Apr 07, 2009 Male patient from CANADA , 71 years of age, weighting 110.2 lb, was diagnosed with haemorrhage and was treated with Niastase (View Usage). Patient experienced the following unwanted or unexpected effects: cardio-respiratory arrest, hypoxic encephalopathy, pulmonary embolism (What is pulmonary embolism?). Niastase dosage: 4.8 Mg, Single.


6147719-2 | Cardio-respiratory Arrest, Hypoxic Encephalopathy, Pulmonary Embolism
on Apr 01, 2009 Male patient from CANADA , 71 years of age, weighting 110.2 lb, was diagnosed with haemorrhage and was treated with Niastase (View Usage). Patient had the following side effects: cardio-respiratory arrest, hypoxic encephalopathy, pulmonary embolism (What is pulmonary embolism?). Niastase dosage: 4.8 Mg, Qd.

6054985-0 | Ischaemic Stroke
Patient was taking Niastase (View Usage). After Niastase was administered, patient had the following side effects: ischaemic stroke on Jan 20, 2009 from CANADA Additional patient health information: Female patient , 79 years of age, weighting 183.0 lb, was diagnosed with haemorrhage and. Niastase dosage: 2.4 Mg, Single.

5961914-4 | Cardiac Arrest, Pulmonary Embolism
Adverse event was reported on Nov 12, 2008 by a Female patient taking Niastase (View Usage) (Dosage: 120 Ug/kg, Unk) . Location: CANADA , 78 years of age, Patient experienced the following unwanted or unexpected effects: cardiac arrest (What is cardiac arrest?), pulmonary embolism (What is pulmonary embolism?).

5948092-2 | Cardiopulmonary Failure, Pulmonary Artery Thrombosis, Pulmonary Oedema
on Nov 01, 2008 Male patient from CANADA , 64 years of age, was diagnosed with haemorrhage and was treated with Niastase (View Usage). Patient had the following side effects: cardiopulmonary failure, pulmonary artery thrombosis, pulmonary oedema. Niastase dosage: 25 Ug/kg, Single.

5935653-X | Pulmonary Artery Thrombosis
on Oct 24, 2008 Male patient from CANADA , 64 years of age, was diagnosed with haemorrhage and was treated with Niastase (View Usage). After Niastase was administered, patient had the following side effects: pulmonary artery thrombosis. Niastase dosage: .

5811495-0 | Cardiac Arrest, Pulmonary Embolism
Patient was taking Niastase (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac arrest (What is cardiac arrest?), pulmonary embolism (What is pulmonary embolism?) on Jul 11, 2008 from CANADA Additional patient health information: Female patient , 78 years of age, . Niastase dosage: 120 Ug/kg, Unk.

5589366-7 | Intestinal Ischaemia
Adverse event was reported on Dec 03, 2007 by a Female patient taking Niastase (View Usage) (Dosage: 4.8 Mg, Unk) was diagnosed with haemorrhage and. Location: CANADA , 48 years of age, weighting 185.2 lb, Patient had the following side effects: intestinal ischaemia. During the same period patient was treated with FRESH FROZEN PLASMA (View Fresh Frozen Plasma Review and Fresh Frozen Plasma Label ), PLATELETS (View Platelets Review and Platelets Label ), RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), ALB (Unk, Unk) (View Alb Review and Alb Label ).

5557212-3 | Renal Failure, Respiratory Tract Infection
on Dec 03, 2007 Female patient from CANADA , 83 years of age, weighting 134.5 lb, was diagnosed with haemorrhage and was treated with Niastase (View Usage). After Niastase was administered, patient had the following side effects: renal failure, respiratory tract infection. Niastase dosage: 90 Ug / Kg Total: 4.8 Mg.

5557211-1 | Intestinal Ischaemia
on Dec 03, 2007 Male patient from CANADA , 20 years of age, was treated with Niastase (View Usage). Patient experienced the following unwanted or unexpected effects: intestinal ischaemia. Niastase dosage: 90 Ug/kg Total: 4.8 Mg,. During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), PLATELETS (View Platelets Review and Platelets Label ), CRYOPRECIPITATES (View Cryoprecipitates Review and Cryoprecipitates Label ), FRESH FROZEN PLASMA (View Fresh Frozen Plasma Review and Fresh Frozen Plasma Label ). Patient was hospitalized.

5557210-X | Arteriosclerosis, Cerebral Infarction, Multi-organ Failure, Renal Failure, Sepsis
Patient was taking Niastase (View Usage). Patient had the following side effects: arteriosclerosis, cerebral infarction, multi-organ failure, renal failure, sepsis (What is sepsis?) on Dec 03, 2007 from CANADA Additional patient health information: Male patient , 78 years of age, weighting 143.3 lb, was diagnosed with haemorrhage and. Niastase dosage: 90 Ug/kg Total: 9.6 Mg. During the same period patient was treated with RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), FRESH FROZEN PLASMA (View Fresh Frozen Plasma Review and Fresh Frozen Plasma Label ), PLATELETS (View Platelets Review and Platelets Label ), ALBUMIN (HUMAN) (View Albumin (human) Review and Albumin (human) Label ).

5553479-6 | Renal Failure
Adverse event was reported on Dec 03, 2007 by a Male patient taking Niastase (View Usage) (Dosage: 7.2 Mg, Unk) was diagnosed with haemorrhage and. Location: CANADA , 38 years of age, After Niastase was administered, patient had the following side effects: renal failure. Patient was hospitalized.

5553477-2 | Intestinal Ischaemia
on Dec 03, 2007 Female patient from CANADA , 48 years of age, weighting 185.2 lb, was diagnosed with haemorrhage and was treated with Niastase (View Usage). Patient experienced the following unwanted or unexpected effects: intestinal ischaemia. Niastase dosage: 4.8 Mg, Unk. During the same period patient was treated with FRESH FROZEN PLASMA (View Fresh Frozen Plasma Review and Fresh Frozen Plasma Label ), PLATELETS (View Platelets Review and Platelets Label ), RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), ALB (Unk, Unk) (View Alb Review and Alb Label ).

5519162-8 | Renal Failure
on Nov 05, 2007 Male patient from CANADA , 38 years of age, was diagnosed with haemorrhage and was treated with Niastase (View Usage). Patient had the following side effects: renal failure. Niastase dosage: 90 Ug/kg Total: 9.6 Mg. Patient was hospitalized.

5513701-9 | Cerebral Infarction
Patient was taking Niastase (View Usage). After Niastase was administered, patient had the following side effects: cerebral infarction on Nov 05, 2007 from CANADA Additional patient health information: Male patient , 78 years of age, was diagnosed with haemorrhage and. Niastase dosage: 90 Ug/kg Total: 9.6 Mg.

5513700-7 | Intestinal Ischaemia
Adverse event was reported on Nov 05, 2007 by a Female patient taking Niastase (View Usage) (Dosage: 90 Ug/kg Total: 4.8 Mg) was diagnosed with haemorrhage and. Location: CANADA , 48 years of age, Patient experienced the following unwanted or unexpected effects: intestinal ischaemia.

5511613-8 | Renal Failure, Respiratory Tract Infection
on Oct 28, 2007 Female patient from CANADA , 83 years of age, was diagnosed with haemorrhage and was treated with Niastase (View Usage). Patient had the following side effects: renal failure, respiratory tract infection. Niastase dosage: 90 Ug / Kg Total: 4.8 Mg.

5511144-5 | Intestinal Ischaemia
on Nov 05, 2007 Male patient from CANADA , 20 years of age, was treated with Niastase (View Usage). After Niastase was administered, patient had the following side effects: intestinal ischaemia. Niastase dosage: 90 Ug/kg Total: 4.8 Mg,.

5468200-X | Cardiac Tamponade, Peripheral Ischaemia, Thrombosis In Device
Patient was taking Niastase (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac tamponade, peripheral ischaemia, thrombosis in device on Jan 24, 2007 from CANADA Additional patient health information: Male patient , 46 years of age, weighting 216.1 lb, was diagnosed with post procedural haemorrhage and. Niastase dosage: 90 Ug/kg, Unk. During the same period patient was treated with APROTININ (View Aprotinin Review and Aprotinin Label ). Patient was hospitalized.

5446017-X | Paraplegia, Spinal Cord Injury, Thrombosis
Adverse event was reported on Feb 16, 2007 by a Female patient taking Niastase (View Usage) (Dosage: 3.6 Mg, Unk) was diagnosed with surgery (What is surgery?) and. Location: CANADA , 17 years of age, weighting 154.3 lb, Patient had the following side effects: paraplegia, spinal cord injury, thrombosis. During the same period patient was treated with HEPARIN (View Heparin Review and Heparin Label ), PROTAMINE SULFATE (View Protamine Sulfate Review and Protamine Sulfate Label ), NIPRIDE (View Nipride Review and Nipride Label ), CRYOPRECIPITATES (View Cryoprecipitates Review and Cryoprecipitates Label ), FRESH FROZEN PLASMA (View Fresh Frozen Plasma Review and Fresh Frozen Plasma Label ), RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), PLATELETS (View Platelets Review and Platelets Label ).

5403704-7 | Haemodynamic Instability
on Jul 24, 2007 Male patient from CANADA , 52 years of age, weighting 165.3 lb, was diagnosed with haemorrhage and was treated with Niastase (View Usage). After Niastase was administered, patient had the following side effects: haemodynamic instability. Niastase dosage: 2.4 Mg, Bid. During the same period patient was treated with ARGATROBAN (View Argatroban Review and Argatroban Label ).

5228590-X | Cardiac Tamponade, Catheter Related Complication, Peripheral Ischaemia
on Jan 24, 2007 Male patient from CANADA , 46 years of age, weighting 216.1 lb, was diagnosed with post procedural haemorrhage and was treated with Niastase (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac tamponade, catheter related complication, peripheral ischaemia. Niastase dosage: 90 Ug/kg, Unk. During the same period patient was treated with APROTININ (View Aprotinin Review and Aprotinin Label ). Patient was hospitalized.

5228576-5 | Cardiac Tamponade, Catheter Related Complication
Patient was taking Niastase (View Usage). Patient had the following side effects: cardiac tamponade, catheter related complication on Jan 24, 2007 from CANADA Additional patient health information: Male patient , 72 years of age, weighting 141.1 lb, was diagnosed with haemorrhage and. Niastase dosage: 3.6 Mg, Single. During the same period patient was treated with BLOOD CELLS, PACKED HUMAN (View Blood Cells, Packed Human Review and Blood Cells, Packed Human Label ), FRESH FROZEN PLASMA (View Fresh Frozen Plasma Review and Fresh Frozen Plasma Label ), PLATELETS (View Platelets Review and Platelets Label ). Patient was hospitalized.

5215947-6 | Cardiac Tamponade, Catheter Related Complication
Adverse event was reported on Jan 12, 2007 by a Male patient taking Niastase (View Usage) (Dosage: 90 Micrograms/kg) was diagnosed with post procedural haemorrhage and. Location: CANADA , 46 years of age, weighting 216.1 lb, After Niastase was administered, patient had the following side effects: cardiac tamponade, catheter related complication. During the same period patient was treated with APROTININ (View Aprotinin Review and Aprotinin Label ). Patient was hospitalized.

5213236-7 | Cardiac Tamponade, Catheter Related Complication
on Jan 07, 2007 Male patient from CANADA , 72 years of age, weighting 141.1 lb, was diagnosed with haemorrhage and was treated with Niastase (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac tamponade, catheter related complication. Niastase dosage: 3.6 Mg, Single. During the same period patient was treated with BLOOD CELLS, PACKED HUMAN (View Blood Cells, Packed Human Review and Blood Cells, Packed Human Label ), FRESH FROZEN PLASMA (View Fresh Frozen Plasma Review and Fresh Frozen Plasma Label ), PLATELETS (View Platelets Review and Platelets Label ). Patient was hospitalized.

5207010-5 | Cardiac Tamponade, Catheter Related Complication
on Jan 07, 2007 Male patient from CANADA , 46 years of age, weighting 216.1 lb, was diagnosed with post procedural haemorrhage and was treated with Niastase (View Usage). Patient had the following side effects: cardiac tamponade, catheter related complication. Niastase dosage: 90 Micrograms/kg. During the same period patient was treated with APROTININ (View Aprotinin Review and Aprotinin Label ). Patient was hospitalized.

5195429-0 | Shock Haemorrhagic
Patient was taking Niastase (View Usage). After Niastase was administered, patient had the following side effects: shock haemorrhagic on Dec 14, 2006 from CANADA Additional patient health information: Male patient , 19 years of age, weighting 154.3 lb, was diagnosed with disseminated intravascular coagulation, shock haemorrhagic and. Niastase dosage: 2.4 Mg, Single. During the same period patient was treated with VASOPRESSIN (.24 U, Qd) (View Vasopressin Review and Vasopressin Label ), ADRENALINE /00003901/ (8.64 Mg, Qd) (View Adrenaline /00003901/ Review and Adrenaline /00003901/ Label ), NOREPHEDRINE HYDROCHLORIDE (23.04 Mg, Qd) (View Norephedrine Hydrochloride Review and Norephedrine Hydrochloride Label ), CIPROFLOXACIN (800 Mg, Qd) (View Ciprofloxacin Review and Ciprofloxacin Label ), RANITIDINE (100 Mg, Qd) (View Ranitidine Review and Ranitidine Label ), FLAGYL /00012501/ (1.5 G, Qd) (View Flagyl /00012501/ Review and Flagyl /00012501/ Label ).

5179034-8 |
Adverse event was reported on Dec 14, 2006 by a Male patient taking Niastase (View Usage) (Dosage: ) was diagnosed with injury and. Location: CANADA , 19 years of age, .

5086807-9 | Hydrocephalus
on Aug 10, 2006 Female patient from CANADA , 66 years of age, was diagnosed with cerebral haemorrhage and was treated with Niastase (View Usage). Patient had the following side effects: hydrocephalus (What is hydrocephalus?). Niastase dosage: 40ug /kg.

4997168-5 | Post Procedural Haemorrhage
on Mar 24, 2006 Female patient from CANADA , 78 years of age, weighting 176.4 lb, was diagnosed with haemorrhage and was treated with Niastase (View Usage). After Niastase was administered, patient had the following side effects: post procedural haemorrhage. Niastase dosage: 1.2 Mg, Single.

4980396-2 | Acute Myocardial Infarction
Patient was taking Niastase (View Usage). Patient experienced the following unwanted or unexpected effects: acute myocardial infarction on Sep 06, 2005 from CANADA Additional patient health information: Male patient , 65 years of age, weighting 176.4 lb, was diagnosed with cerebellar haemorrhage and. Niastase dosage: 40 Ug/kg, Unk.

4798345-9 | Acute Myocardial Infarction, Troponin Increased
Adverse event was reported on Sep 06, 2005 by a Male patient taking Niastase (View Usage) (Dosage: 40 Ug/kg, Unk) was diagnosed with cerebellar haemorrhage and. Location: CANADA , 65 years of age, weighting 176.4 lb, Patient had the following side effects: acute myocardial infarction, troponin increased.

4773129-6 | Troponin Increased
on Sep 06, 2005 Female patient from CANADA , child 0 years of age, was diagnosed with cerebellar haemorrhage and was treated with Niastase (View Usage). After Niastase was administered, patient had the following side effects: troponin increased. Niastase dosage: 40 Ug/kg, Unk.

4682627-5 | Fungal Infection, Multi-organ Failure, Portal Vein Thrombosis
on Apr 26, 2005 Female patient from , 66 years of age, weighting 207.2 lb, was diagnosed with off label use and was treated with Niastase (View Usage). Patient experienced the following unwanted or unexpected effects: fungal infection (What is fungal infection?), multi-organ failure, portal vein thrombosis. Niastase dosage: 4.8 Mg, Single. Patient was hospitalized.

4661280-0 | Fungal Infection, Multi-organ Failure, Portal Vein Thrombosis
Patient was taking Niastase (View Usage). Patient had the following side effects: fungal infection (What is fungal infection?), multi-organ failure, portal vein thrombosis on Apr 26, 2005 from Additional patient health information: Female patient , 66 years of age, weighting 207.2 lb, was diagnosed with off label use and. Niastase dosage: 4.8 Mg, Single. Patient was hospitalized.

4656605-6 | Concomitant Disease Progression, Hydrocephalus
Adverse event was reported on Mar 23, 2005 by a Male patient taking Niastase (View Usage) (Dosage: 3.4 Mg, Qd) was diagnosed with cerebral haemorrhage and. Location: , 80 years of age, After Niastase was administered, patient had the following side effects: concomitant disease progression, hydrocephalus (What is hydrocephalus?). Patient was hospitalized.

4655886-2 | Portal Vein Thrombosis
on Apr 26, 2005 Female patient from , 66 years of age, weighting 207.2 lb, was diagnosed with off label use and was treated with Niastase (View Usage). Patient experienced the following unwanted or unexpected effects: portal vein thrombosis. Niastase dosage: 2 Doses Of 4.8 Mg. Patient was hospitalized.

4650776-3 | Cerebral Haemorrhage, Loss Of Consciousness, Neutropenia
on Feb 18, 2005 Male patient from , 53 years of age, weighting 205.0 lb, was diagnosed with haemorrhage and was treated with Niastase (View Usage). Patient had the following side effects: cerebral haemorrhage, loss of consciousness, neutropenia. Niastase dosage: 7.2 Mg, 2 Doses. During the same period patient was treated with AMIODARONE (150 Mg, Single) (View Amiodarone Review and Amiodarone Label ), BISACODYL (View Bisacodyl Review and Bisacodyl Label ), CALCIUM GLUCONATE (2 Doses) (View Calcium Gluconate Review and Calcium Gluconate Label ), CHLORHEXIDINE (10-15 Ml Mouthwash) (View Chlorhexidine Review and Chlorhexidine Label ), CIPROFLOXACIN (400 Mg, Qd) (View Ciprofloxacin Review and Ciprofloxacin Label ), NIMBEX (2 Mg, Qd) (View Nimbex Review and Nimbex Label ), COUMADIN (Oral Dose According To Inr) (View Coumadin Review and Coumadin Label ).

4617234-3 | Loss Of Consciousness, Neutropenia
Patient was taking Niastase (View Usage). After Niastase was administered, patient had the following side effects: loss of consciousness, neutropenia on Feb 18, 2005 from Additional patient health information: Male patient , 53 years of age, weighting 205.0 lb, was diagnosed with haemorrhage and. Niastase dosage: 7.2 Mg, 2 Doses. During the same period patient was treated with AMIODARONE (150 Mg, Single) (View Amiodarone Review and Amiodarone Label ), BISACODYL (View Bisacodyl Review and Bisacodyl Label ), CALCIUM GLUCONATE (2 Doses) (View Calcium Gluconate Review and Calcium Gluconate Label ), CHLORHEXIDINE (10-15 Ml Mouthwash) (View Chlorhexidine Review and Chlorhexidine Label ), CIPROFLOXACIN (400 Mg, Qd) (View Ciprofloxacin Review and Ciprofloxacin Label ), CISATRACURIUM (2 Mg, Qd) (View Cisatracurium Review and Cisatracurium Label ), COUMADIN (Oral Dose According To Inr) (View Coumadin Review and Coumadin Label ).

4608548-1 | Cerebral Haemorrhage, Neutropenia, Renal Failure
Adverse event was reported on Feb 18, 2005 by a Male patient taking Niastase (View Usage) (Dosage: 7.2 Mg, 2 Doses) was diagnosed with haemorrhage and. Location: , 53 years of age, weighting 205.0 lb, Patient experienced the following unwanted or unexpected effects: cerebral haemorrhage, neutropenia, renal failure. During the same period patient was treated with AMIODARONE HCL (150 Mg, Single) (View Amiodarone Hcl Review and Amiodarone Hcl Label ), BISACODYL (View Bisacodyl Review and Bisacodyl Label ), CALCIUM GLUCONATE (2 Doses) (View Calcium Gluconate Review and Calcium Gluconate Label ), CHLORHEXIDINE (10-15 Ml Mouthwash) (View Chlorhexidine Review and Chlorhexidine Label ), CIPROFLOXACIN (400 Mg, Qd) (View Ciprofloxacin Review and Ciprofloxacin Label ), CISATRACURIUM (2 Mg, Qd) (View Cisatracurium Review and Cisatracurium Label ), COUMADIN (Oral Dose According To Inr) (View Coumadin Review and Coumadin Label ).